Novo Nordisk's Wegovy Pill Shows Early Weight Loss Gains in…

Event summary

Novo Nordisk presented real-world data from the OCTANE study showing patients switching from injectable GLP-1 therapies to Wegovy pill lost 4.1% body weight on average after three months.
40.7% of participants achieved 5% or more weight loss, and the proportion of participants with BMI ≥30 kg/m² decreased by 21.6 percentage points.
The study analyzed de-identified data from 194 patients on the Ro telehealth platform who switched from injectable semaglutide or tirzepatide to oral semaglutide between January 5, 2026, and February 7, 2026.
Wegovy pill is currently launched in the US, United Arab Emirates, UK, and Germany, with plans to expand to select markets in the coming quarters.

The big picture

Novo Nordisk's real-world data on the Wegovy pill underscores the growing trend of patients preferring oral medications over injectables for weight management. This shift aligns with broader industry movements towards patient-centric care and the increasing demand for convenient, effective obesity treatments. The strategic collaboration with Ro telehealth platform highlights Novo Nordisk's focus on leveraging real-world evidence to support its product offerings.

What we're watching

Market Expansion: The pace at which Novo Nordisk can expand the Wegovy pill's market reach beyond current regions.
Long-Term Efficacy: Whether the early weight loss and lifestyle improvements observed in the OCTANE study can be sustained over longer periods.
Competitive Positioning: How Novo Nordisk's oral semaglutide compares to other weight-loss treatments in terms of patient preference and clinical outcomes.